ZF2001: Perbedaan antara revisi

Jelajahi riwayat secara interaktif

← Revisi sebelumnya

Konten dihapus Konten ditambahkan

VisualTeks wiki

Revisi per 28 Juli 2021 13.42 sunting RaFaDa20631 (bicara \| kontrib) Pengurus 86.144 suntingan k Moving from Category:Vaksin COVID-19 to Category:Redirects connected to a Wikidata item using Cat-a-lot ← Revisi sebelumnya		Revisi terkini sejak 21 November 2022 09.23 sunting balikkan Tacsipacsi (bicara \| kontrib) 25 suntingan k Menghapus Kategori:Redirects connected to a Wikidata item menggunakan HotCat Tag: halaman dengan galat kutipan
(8 revisi perantara oleh 6 pengguna tidak ditampilkan)
Baris 2: \| type = vaccine \| image = \| vaccine_type = Vaksin subunit (protein) \| target = [[~~COVID~~SARS-19CoV-2]] \| tradename = Zifivax (RBD-Dimer) \| Drugs.com = \| MedlinePlus = Baris 32: \| Verifiedfields = }} '''ZF2001''', bernama dagang '''~~RBD~~ZIFIVAX''' atau '''ZF-~~Dimer~~UZ-VAC-2001''', adalah sebuah [[vaksin COVID-19]] [[vaksin subunit\|subunit protein]] yang dikembangkan oleh Anhui Zhifei Longcom dalam kolaborasi dengan Institut Mikrobiologi di [[Akademi Sains Tiongkok]].<ref name=":0">{{Cite web\|title=Anhui Zhifei Longcom: RBD-Dimer – COVID19 Vaccine Tracker\|url=https://covid19.trackvaccines.org/vaccines/27/\|access-date=2020-12-27\|website=covid19.trackvaccines.org}}</ref><ref>{{Cite web\|title=COVID-19 Vaccine: RBD-Dimer by Anhui Zhifei Longcom Biopharma, Institute of Microbiology Chinese Academy of Sciences\|url=https://covidvax.org/covid19-vaccine/AnhuiZhifei/Adjuvanted-recombinant-protein-Anhui-Zhifei-Longcom-Biopharma-Institute-of-Microbiology-Chinese-Acad\|access-date=2020-12-27\|website=covidvax.org\|language=en\|archive-date=2021-01-30\|archive-url=https://web.archive.org/web/20210130172708/https://covidvax.org/covid19-vaccine/AnhuiZhifei/Adjuvanted-recombinant-protein-Anhui-Zhifei-Longcom-Biopharma-Institute-of-Microbiology-Chinese-Acad\|dead-url=yes}}</ref> Pada Desember 2020, kandidat vaksin tersebut menjalani pengujian tahap III dengan 29.000 partisipan di [[Tiongkok]], [[Ekuador]], [[Indonesia]], [[Malaysia]], [[Pakistan]], dan [[Uzbekistan]].<ref>{{Cite web\|date=2020-11-20\|title=Fifth Chinese Covid-19 vaccine candidate ready to enter phase 3 trials\|url=https://www.scmp.com/news/china/science/article/3110690/coronavirus-chinas-cnbg-set-review-covid-19-vaccine-phase-3\|access-date=2020-12-27\|website=South China Morning Post\|language=en}}</ref><ref name=":4" /> Jika pengujian tersebut berhasil, perusahaan tersebut berrencana untuk membuat 300 juta dosis vaksin setiap tahun.<ref name=":2" /> == Penggunaan medis == Vaksin ini diberikan dalam 3 dosis selama periode 2 bulan.<ref>{{Cite web\|date=2021-03-17\|title=China’s production bottleneck ‘could be eased with latest Covid-19 vaccine’\|url=https://www.scmp.com/news/china/science/article/3125809/chinas-production-bottleneck-could-be-eased-latest-covid-19\|website=South China Morning Post\|language=en\|access-date=2021-10-08}}</ref> == Efikasi == Pada Agustus 2021, pada uji coba Fase III, ZF2001 dilaporkan memiliki efikasi 81,76% terhadap COVID-19, hal ini berdasarkan analisis sementara terhadap 221 infeksi COVID-19 dalam penelitian terhadap 28.500 orang.<ref>{{Cite news\|last=Reuters\|date=2021-08-27\|title=China's Zhifei says unit's COVID shot shows 81.76% efficacy in late-stage trial\|url=https://www.reuters.com/world/china/chinas-zhifei-units-covid-19-shot-shows-8176-efficacy-late-stage-trial-2021-08-27/\|newspaper=Reuters\|language=en\|access-date=2021-10-08}}</ref><ref name=":1">{{Cite news\|date=2021-08-27\|title=New Chinese vaccine shows 82% effectiveness against serious Covid-19\|url=https://www.straitstimes.com/asia/east-asia/new-chinese-vaccine-shows-82-effectiveness-against-serious-covid-19\|newspaper=The Straits Times\|language=en\|issn=0585-3923\|access-date=2021-10-08}}</ref> == Varian == Pada Agustus 2021, pada uji coba Fase III dilaporkan ZF 2001 memiliki efikasi 93% terhadap varian Alpha dan 78% terhadap varian Delta.<ref name=":1" /> Pada Juli 2021, penelitian laboratorium menunjukkan ZF2001 mempertahankan efek penetral terhadap B.1.429 (Epsilon), B.1.351(Beta), P.1(Gamma), B.1.525(Eta), B.1.617.1(Kappa), titer penetral menurun mulai dari 1,1 kali lipat menjadi 2,1 kali lipat, tetapi efek penetralnya masih baik.<ref>{{Cite journal\|last=Zhao\|first=Xin\|last2=Zheng\|first2=Anqi\|last3=Li\|first3=Dedong\|last4=Zhang\|first4=Rong\|last5=Sun\|first5=Huan\|last6=Wang\|first6=Qihui\|last7=Gao\|first7=George F\|last8=Han\|first8=Pengcheng\|last9=Dai\|first9=Lianpan\|date=2021-10\|title=Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants\|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378832/\|journal=The Lancet. Microbe\|volume=2\|issue=10\|pages=e494\|doi=10.1016/S2666-5247(21)00217-2\|issn=2666-5247\|pmc=8378832\|pmid=34458880}}</ref> == Lihat pula == Baris 44 ⟶ 55: {{Reflist\|35em}}{{Authority control}}{{COVID-19}} [[Kategori:~~Redirects~~Vaksin ~~connected to a Wikidata item~~Covid-19]]